# StemSight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stemsight

- Industry: Biotechnology
- Headquarters: Tampere, Finland
- Website: www.stemsight.fi
- Total disclosed funding: $0.6M
- Latest round: Seed (Sep 13, 2021)
- Investors on record: 2

## About

Based in Finland, StemSight Oy specializes in innovative cell therapies aimed at treating corneal blindness through advanced applications of induced pluripotent stem cells and bioprinting technology.StemSight Oy, founded in 2021 and headquartered in Tampere, Finland, focuses on developing stem cell-based therapies for corneal blindness. The company was co-founded by Heli Skottman and Laura Koivusalo, the latter of whom also serves as CEO. As of February 2025, StemSight has successfully raised a total of EUR 2.3 million across multiple funding rounds, with the latest round led by Voima Ventures, including participation from Stephen Industries, Biothom, and Business Finland Venture Capital.StemSight specializes in off-the-shelf cell therapies aimed at addressing corneal blindness through innovative applications of induced pluripotent stem (iPS) cells combined with functional biomaterials. Their core product offerings focus on developing biocompatible corneal tissues, particularly through their involvement in the EU-funded KeratOPrinter project, which utilizes advanced bioprinting technology to create full-thickness corneas. This innovation provides an alternative to traditional donor tissues, enhancing accessibility to vision-restoration therapies for patients suffering from corneal blindness, targeting healthcare providers and research institutions across multiple EU countries.In the most recent year, 2023, StemSight reported a revenue of EUR 0, with an EBITDA of EUR -399,094.2. Their revenue generation is primarily derived from strategic collaborations in initiatives like the KeratOPrinter project, with expected transactions from healthcare facilities and research institutions utilizing their bioprinted corneal tissues for clinical applications.On February 13, 2025, StemSight Oy raised EUR 2.3 million in venture funding to further its mission of promoting stem cell-based treatments for corneal blindness caused by limbal stem cell deficit. This funding will support the development of new products, with an emphasis on expanding their bioprinting capabilities and enhancing the accessibility of their therapies. The company is also targeting expansion into new European markets to increase its reach and impact in treating corneal blindness.

## Funding rounds

- Seed, Sep 13, 2021, $0.6M — Avohoidon Tutkimussäätiö, Voima Ventures

## Investors

- Avohoidon Tutkimussäätiö — Seed
- Voima Ventures (https://capitalatlas.ai/funds/voima-ventures) — Seed